animal refuge boxes to encourage wildlife in the surrounding region, as well as more than 1,100 solar panels to generate electricity for the portion of the building.
The facility, which is scheduled to open in 2024, will support both the regulatory-approved cannabis-based medications of the firm, as well as support potential capacity for other treatments that are in progress. Chris Tovey, executive vice president of Jazz Pharmaceuticals, expressed hopes over the new establishment. He said, “The UK has been our home for over two decades. This strategic investment underlines Jazz’s continued commitment to the UK and will help us bring potentially life-changing medicines to more patients who desperately need them in the UK and around the world”.
Chris expressed confidence over the company’s progress in the future. He said, “We are thrilled to have commenced construction of this state-of-the-art facility in Kent, which will create more than 100 permanent, highly skilled jobs”. He added, “This facility, which is expected to open in 2024, will not only significantly increase our ability to support the growing demand for our medicines, but help us maintain our position as a world leader in cannabinoid science.”
The new facility will cover around 60,000 square feet in size and will cost approximately £75 million. Once opened, the plant is expected to generate over 100 additional high-skilled employment opportunities. George Freeman MP, science, research and innovation minister, expressed pride over the company’s new venture. He said, “This £75m investment by Jazz Pharmaceuticals in a state-of-the-art pharmaceutical manufacturing facility is a big sign of confidence in the UK life science ecosystem. Not only will this investment support the creation of over 100 additional highly skilled jobs in the region, it is a sign of UK expertise in cannabinoid science and medicines serving the UK and beyond.”
